LuciaSeminario VidalMDPhD

Clinical Trials

• A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma Start of enrollment: 2013 May 30

  Completed

  Phase 3

• Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma Start of enrollment: 2014 Nov 12

  Completed

• FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) Start of enrollment: 2015 Dec 01

  Completed

  Phase 3

• Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL Start of enrollment: 2017 Jan 01

  Terminated

  Phase 3

• Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis Start of enrollment: 2017 Mar 28

  Completed

  Phase 3

• Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis Start of enrollment: 2018 Jun 25

  Completed

  Phase 3

• A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Nov 14

  Terminated

  Phase 2

• Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 May 31

  Completed

  Phase 2

• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis Start of enrollment: 2018 Jul 26

  Completed

  Phase 3

• This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). Start of enrollment: 2019 Jan 31

  Completed

  Phase 3

• Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis Start of enrollment: 2019 Jan 31

  Completed

  Phase 2

• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) Start of enrollment: 2020 Nov 17

  Completed

  Phase 3

• Join now to see all